Coya Therapeutics, Inc.
We are a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (“Tregs”). Tregs consist of CD4+CD25high hFOXP3+ cells, which are a sub-population of T-lymphocytes, a type of white blood cell that suppresses inflammatory responses. We are initially focused on developing our Treg-based therapies for neurodegenerative, autoimmune […]
November 20, 2022 Read More